Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oric Pharmaceuticals (ORIC) Gains from Investment Securities (2019 - 2026)

Oric Pharmaceuticals filings provide 8 years of Gains from Investment Securities readings, the most recent being $3.4 million for Q1 2026.

  • Quarterly Gains from Investment Securities rose 13.9% to $3.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.4 million through Mar 2026, up 13.9% year-over-year, with the annual reading at $13.9 million for FY2025, 23.58% up from the prior year.
  • Gains from Investment Securities hit $3.4 million in Q1 2026 for Oric Pharmaceuticals, down from $13.9 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $13.9 million in Q4 2025 and bottomed at $43445.0 in Q3 2023.
  • Average Gains from Investment Securities over 5 years is $4.7 million, with a median of $3.4 million recorded in 2026.
  • The largest annual shift saw Gains from Investment Securities crashed 99.1% in 2023 before it soared 1361.45% in 2025.
  • Oric Pharmaceuticals' Gains from Investment Securities stood at $6.7 million in 2022, then surged by 30.27% to $8.7 million in 2023, then increased by 29.07% to $11.2 million in 2024, then grew by 23.58% to $13.9 million in 2025, then crashed by 75.86% to $3.4 million in 2026.
  • Per Business Quant, the three most recent readings for ORIC's Gains from Investment Securities are $3.4 million (Q1 2026), $13.9 million (Q4 2025), and $3.4 million (Q3 2025).